Loading…

Quality control for serological testing

•Integrated approach to quality control of serological assays.•QC rule targets are obtained from a large manufacturer database of laboratory performance.•Lot-to-lot reagent variation assessed before reagent use. The quality control of serological assays remains controversial. The aim of this project...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2025-01, Vol.564, p.119905, Article 119905
Main Authors: Badrick, Tony, Fortun, Mickael, Vayanos, Zoe, Bernard, Mathieu, Dufour, Philippe, Souied, Laurent, Giannoli, Jean-Marc
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c305t-d46c02bb4dd0bb11cb25e1771fbc8731d37d75e8578f84d3392bc04dc50ed9883
container_end_page
container_issue
container_start_page 119905
container_title Clinica chimica acta
container_volume 564
creator Badrick, Tony
Fortun, Mickael
Vayanos, Zoe
Bernard, Mathieu
Dufour, Philippe
Souied, Laurent
Giannoli, Jean-Marc
description •Integrated approach to quality control of serological assays.•QC rule targets are obtained from a large manufacturer database of laboratory performance.•Lot-to-lot reagent variation assessed before reagent use. The quality control of serological assays remains controversial. The aim of this project was to describe the problems associated with a working model for controlling these assays and solutions, including using a source of well-defined targets and acceptable limits, a process to identify lot-to-lot reagent variation and an interpretation of the result that accounted for the clinical situation. False-negative results are problematic but can be reduced by identifying and comparing reagent lot variation with previous results. The components of the Quality Assurance strategy are the following: Lot-to-lot reagent and calibrator variation assessment; dynamic, big-data approach to determine accurate targets and acceptable limits for manufacturer-provided QC material; negative QC monitoring process; use of commutable EQA with a sufficient method subgroup size to assess bias; clinical assessment of any statistically flagged error; and provision of support to the clinician for the interpretation of results. The model described has been used for twelve months, and acceptable variation has been maintained. The paper presents a solution that emphasizes the early detection of reagent lot variation and patient risk rather than instrument control. Reducing the risk of a false result to patients requires optimal assay quality control and an effective mechanism to support the clinician’s use of these results in diagnosis and monitoring. The problems of serological assays are well-known, but there remain few integrated solutions in the literature.
doi_str_mv 10.1016/j.cca.2024.119905
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3091288113</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009898124021582</els_id><sourcerecordid>3091288113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-d46c02bb4dd0bb11cb25e1771fbc8731d37d75e8578f84d3392bc04dc50ed9883</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotlZ_gBfZm152nUl2uwmepPgFBRH0HDYfW1K2G012hf57U1o9epoZeOeddx5CLhEKBJzfrgutm4ICLQtEIaA6IlPkNctZKegxmQKAyLngOCFnMa7TWMIcT8mECaQ1FWJKrt_GpnPDNtO-H4LvstaHLNrU-ZXTTZcNNg6uX52Tk7bpor041Bn5eHx4Xzzny9enl8X9MtcMqiE35VwDVao0BpRC1IpWFusaW6VTMDSsNnVleVXzlpeGMUGVhtLoCqwRnLMZudn7fgb_NabbcuOitl3X9NaPUTJI0TlHZEmKe6kOPsZgW_kZ3KYJW4kgd3zkWiY-csdH7vmknauD_ag21vxt_AJJgru9wKYnv50NMmpne22NC1YP0nj3j_0P0e10RQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3091288113</pqid></control><display><type>article</type><title>Quality control for serological testing</title><source>ScienceDirect Freedom Collection</source><creator>Badrick, Tony ; Fortun, Mickael ; Vayanos, Zoe ; Bernard, Mathieu ; Dufour, Philippe ; Souied, Laurent ; Giannoli, Jean-Marc</creator><creatorcontrib>Badrick, Tony ; Fortun, Mickael ; Vayanos, Zoe ; Bernard, Mathieu ; Dufour, Philippe ; Souied, Laurent ; Giannoli, Jean-Marc</creatorcontrib><description>•Integrated approach to quality control of serological assays.•QC rule targets are obtained from a large manufacturer database of laboratory performance.•Lot-to-lot reagent variation assessed before reagent use. The quality control of serological assays remains controversial. The aim of this project was to describe the problems associated with a working model for controlling these assays and solutions, including using a source of well-defined targets and acceptable limits, a process to identify lot-to-lot reagent variation and an interpretation of the result that accounted for the clinical situation. False-negative results are problematic but can be reduced by identifying and comparing reagent lot variation with previous results. The components of the Quality Assurance strategy are the following: Lot-to-lot reagent and calibrator variation assessment; dynamic, big-data approach to determine accurate targets and acceptable limits for manufacturer-provided QC material; negative QC monitoring process; use of commutable EQA with a sufficient method subgroup size to assess bias; clinical assessment of any statistically flagged error; and provision of support to the clinician for the interpretation of results. The model described has been used for twelve months, and acceptable variation has been maintained. The paper presents a solution that emphasizes the early detection of reagent lot variation and patient risk rather than instrument control. Reducing the risk of a false result to patients requires optimal assay quality control and an effective mechanism to support the clinician’s use of these results in diagnosis and monitoring. The problems of serological assays are well-known, but there remain few integrated solutions in the literature.</description><identifier>ISSN: 0009-8981</identifier><identifier>ISSN: 1873-3492</identifier><identifier>EISSN: 1873-3492</identifier><identifier>DOI: 10.1016/j.cca.2024.119905</identifier><identifier>PMID: 39127299</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Lot-to-lot variation ; Network assay control ; Serological assay</subject><ispartof>Clinica chimica acta, 2025-01, Vol.564, p.119905, Article 119905</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c305t-d46c02bb4dd0bb11cb25e1771fbc8731d37d75e8578f84d3392bc04dc50ed9883</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27898,27899</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39127299$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Badrick, Tony</creatorcontrib><creatorcontrib>Fortun, Mickael</creatorcontrib><creatorcontrib>Vayanos, Zoe</creatorcontrib><creatorcontrib>Bernard, Mathieu</creatorcontrib><creatorcontrib>Dufour, Philippe</creatorcontrib><creatorcontrib>Souied, Laurent</creatorcontrib><creatorcontrib>Giannoli, Jean-Marc</creatorcontrib><title>Quality control for serological testing</title><title>Clinica chimica acta</title><addtitle>Clin Chim Acta</addtitle><description>•Integrated approach to quality control of serological assays.•QC rule targets are obtained from a large manufacturer database of laboratory performance.•Lot-to-lot reagent variation assessed before reagent use. The quality control of serological assays remains controversial. The aim of this project was to describe the problems associated with a working model for controlling these assays and solutions, including using a source of well-defined targets and acceptable limits, a process to identify lot-to-lot reagent variation and an interpretation of the result that accounted for the clinical situation. False-negative results are problematic but can be reduced by identifying and comparing reagent lot variation with previous results. The components of the Quality Assurance strategy are the following: Lot-to-lot reagent and calibrator variation assessment; dynamic, big-data approach to determine accurate targets and acceptable limits for manufacturer-provided QC material; negative QC monitoring process; use of commutable EQA with a sufficient method subgroup size to assess bias; clinical assessment of any statistically flagged error; and provision of support to the clinician for the interpretation of results. The model described has been used for twelve months, and acceptable variation has been maintained. The paper presents a solution that emphasizes the early detection of reagent lot variation and patient risk rather than instrument control. Reducing the risk of a false result to patients requires optimal assay quality control and an effective mechanism to support the clinician’s use of these results in diagnosis and monitoring. The problems of serological assays are well-known, but there remain few integrated solutions in the literature.</description><subject>Lot-to-lot variation</subject><subject>Network assay control</subject><subject>Serological assay</subject><issn>0009-8981</issn><issn>1873-3492</issn><issn>1873-3492</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LAzEQhoMotlZ_gBfZm152nUl2uwmepPgFBRH0HDYfW1K2G012hf57U1o9epoZeOeddx5CLhEKBJzfrgutm4ICLQtEIaA6IlPkNctZKegxmQKAyLngOCFnMa7TWMIcT8mECaQ1FWJKrt_GpnPDNtO-H4LvstaHLNrU-ZXTTZcNNg6uX52Tk7bpor041Bn5eHx4Xzzny9enl8X9MtcMqiE35VwDVao0BpRC1IpWFusaW6VTMDSsNnVleVXzlpeGMUGVhtLoCqwRnLMZudn7fgb_NabbcuOitl3X9NaPUTJI0TlHZEmKe6kOPsZgW_kZ3KYJW4kgd3zkWiY-csdH7vmknauD_ag21vxt_AJJgru9wKYnv50NMmpne22NC1YP0nj3j_0P0e10RQ</recordid><startdate>20250101</startdate><enddate>20250101</enddate><creator>Badrick, Tony</creator><creator>Fortun, Mickael</creator><creator>Vayanos, Zoe</creator><creator>Bernard, Mathieu</creator><creator>Dufour, Philippe</creator><creator>Souied, Laurent</creator><creator>Giannoli, Jean-Marc</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20250101</creationdate><title>Quality control for serological testing</title><author>Badrick, Tony ; Fortun, Mickael ; Vayanos, Zoe ; Bernard, Mathieu ; Dufour, Philippe ; Souied, Laurent ; Giannoli, Jean-Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-d46c02bb4dd0bb11cb25e1771fbc8731d37d75e8578f84d3392bc04dc50ed9883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Lot-to-lot variation</topic><topic>Network assay control</topic><topic>Serological assay</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Badrick, Tony</creatorcontrib><creatorcontrib>Fortun, Mickael</creatorcontrib><creatorcontrib>Vayanos, Zoe</creatorcontrib><creatorcontrib>Bernard, Mathieu</creatorcontrib><creatorcontrib>Dufour, Philippe</creatorcontrib><creatorcontrib>Souied, Laurent</creatorcontrib><creatorcontrib>Giannoli, Jean-Marc</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinica chimica acta</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Badrick, Tony</au><au>Fortun, Mickael</au><au>Vayanos, Zoe</au><au>Bernard, Mathieu</au><au>Dufour, Philippe</au><au>Souied, Laurent</au><au>Giannoli, Jean-Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality control for serological testing</atitle><jtitle>Clinica chimica acta</jtitle><addtitle>Clin Chim Acta</addtitle><date>2025-01-01</date><risdate>2025</risdate><volume>564</volume><spage>119905</spage><pages>119905-</pages><artnum>119905</artnum><issn>0009-8981</issn><issn>1873-3492</issn><eissn>1873-3492</eissn><abstract>•Integrated approach to quality control of serological assays.•QC rule targets are obtained from a large manufacturer database of laboratory performance.•Lot-to-lot reagent variation assessed before reagent use. The quality control of serological assays remains controversial. The aim of this project was to describe the problems associated with a working model for controlling these assays and solutions, including using a source of well-defined targets and acceptable limits, a process to identify lot-to-lot reagent variation and an interpretation of the result that accounted for the clinical situation. False-negative results are problematic but can be reduced by identifying and comparing reagent lot variation with previous results. The components of the Quality Assurance strategy are the following: Lot-to-lot reagent and calibrator variation assessment; dynamic, big-data approach to determine accurate targets and acceptable limits for manufacturer-provided QC material; negative QC monitoring process; use of commutable EQA with a sufficient method subgroup size to assess bias; clinical assessment of any statistically flagged error; and provision of support to the clinician for the interpretation of results. The model described has been used for twelve months, and acceptable variation has been maintained. The paper presents a solution that emphasizes the early detection of reagent lot variation and patient risk rather than instrument control. Reducing the risk of a false result to patients requires optimal assay quality control and an effective mechanism to support the clinician’s use of these results in diagnosis and monitoring. The problems of serological assays are well-known, but there remain few integrated solutions in the literature.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>39127299</pmid><doi>10.1016/j.cca.2024.119905</doi></addata></record>
fulltext fulltext
identifier ISSN: 0009-8981
ispartof Clinica chimica acta, 2025-01, Vol.564, p.119905, Article 119905
issn 0009-8981
1873-3492
1873-3492
language eng
recordid cdi_proquest_miscellaneous_3091288113
source ScienceDirect Freedom Collection
subjects Lot-to-lot variation
Network assay control
Serological assay
title Quality control for serological testing
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T19%3A01%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20control%20for%20serological%20testing&rft.jtitle=Clinica%20chimica%20acta&rft.au=Badrick,%20Tony&rft.date=2025-01-01&rft.volume=564&rft.spage=119905&rft.pages=119905-&rft.artnum=119905&rft.issn=0009-8981&rft.eissn=1873-3492&rft_id=info:doi/10.1016/j.cca.2024.119905&rft_dat=%3Cproquest_cross%3E3091288113%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c305t-d46c02bb4dd0bb11cb25e1771fbc8731d37d75e8578f84d3392bc04dc50ed9883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3091288113&rft_id=info:pmid/39127299&rfr_iscdi=true